Skip to content
Abierto
Menu

Solicitation, first published as award notice

PREVENT IDIQ MATO RFP

75N91023R00024

National Institutes of Health, NIH NCI. Research and Development in Biotechnology (except Nanobiotechnology).

View on SAM.govMarkdown

Awarded

Iit Research Institute

$0.00 obligated so far on USAspending

Description

As published on SAM.gov.

Amendment 02 is to issue minor changes to solicitation, 75N91023R00024, for the PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing. See attached for additional details.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Iit Research Institute
UEI
DGBUFQYMKWB5
CAGE
03889
Vendor location
Chicago, IL
Contract
75N91024D00001
Obligated
$0.00, potential $149,995,000
Actions
7 between January 23, 2024 and July 15, 2026
Competition
Full and Open Competition, 9 offers received
Set-aside reported
No Set Aside Used.
Described as
Prevent Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing
Match
solicitation number 75N91023R00024 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
Record
USAspending award page
Recipient
University of Illinois
UEI
W8XEAJDKMXH3
CAGE
1YGW1
Vendor location
Chicago, IL
Contract
75N91024D00002
Obligated
$0.00, potential $149,995,000
Actions
4 between January 23, 2024 and January 31, 2025
Competition
Full and Open Competition, 9 offers received
Set-aside reported
No Set Aside Used.
Described as
Prevent Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing
Match
solicitation number 75N91023R00024 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
Record
USAspending award page
Recipient
The Institute for Cancer Research
UEI
FF1XVJMDYVR1
CAGE
1RAF4
Vendor location
Philadelphia, PA
Contract
75N91024D00003
Obligated
$0.00, potential $149,995,000
Actions
5 between January 24, 2024 and June 29, 2026
Competition
Full and Open Competition, 9 offers received
Set-aside reported
No Set Aside Used.
Described as
Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ Contract in Support of the Prevent Cancer Preclinical Drug Development Program
Match
solicitation number 75N91023R00024 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
Record
USAspending award page
Recipient
The Univeristy of Texas M.D. Anderson Cancer Center
UEI
S3GMKS8ELA16
CAGE
0KD38
Vendor location
Houston, TX
Contract
75N91024D00004
Obligated
$0.00, potential $149,995,000
Actions
5 between January 24, 2024 and June 30, 2026
Competition
Full and Open Competition, 9 offers received
Set-aside reported
No Set Aside Used.
Described as
Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ Contract in Support of the Prevent Cancer Preclinical Drug Development Program
Match
solicitation number 75N91023R00024 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
Record
USAspending award page
Recipient
University of Oklahoma
UEI
GY8NMUZQXVS7
CAGE
4B862
Vendor location
Oklahoma City, OK
Contract
75N91024D00005
Obligated
$0.00, potential $149,995,000
Actions
6 between January 24, 2024 and July 9, 2026
Competition
Full and Open Competition, 9 offers received
Set-aside reported
No Set Aside Used.
Described as
Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ Contract in Support of the Prevent Cancer Preclinical Drug Development Program
Match
solicitation number 75N91023R00024 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
Record
USAspending award page
Recipient
Weill Medical College of Cornell University
UEI
YNT8TCJH8FQ8
CAGE
1UMU6
Vendor location
New York, NY
Contract
75N91024D00006
Obligated
$0.00, potential $149,995,000
Actions
5 between January 24, 2024 and August 31, 2026
Competition
Full and Open Competition, 9 offers received
Set-aside reported
No Set Aside Used.
Described as
Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ Contract in Support of the Prevent Cancer Preclinical Drug Development Program
Match
solicitation number 75N91023R00024 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
Record
USAspending award page
Recipient
Curia Bio Inc.
UEI
PW5LPREDN9N5
CAGE
9TMX2
Vendor location
Belmont, CA
Contract
75N91024D00008
Obligated
$0.00, potential $149,995,000
Actions
2 between September 13, 2024 and June 25, 2026
Competition
Full and Open Competition, 2 offers received
Set-aside reported
No Set Aside Used.
Described as
Prevent Cancer Preclinical Drug Development Program: CGMP
Match
solicitation number 75N91023R00024 equals the FPDS solicitation identifier; same awarding office 75N910 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. January 23, 2024

    Award notice, originally solicitation

    PREVENT Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing

    Awarded to IIT RESEARCH INSTITUTE Chicago for $149,995,000. SAM.gov, notice 565b59bb59ae4ce0ba0d74bd4fefd012

  2. February 1, 2024

    Award notice

    PREVENT Preclinical Efficacy & Endpoint Biomarkers

    Awarded to The Institute for Cancer Research 333 Cottman Avenue Philadelphia PA 191112434 US for $149,995,000. SAM.gov, notice 045272fa52024c0fa6f50c0158581e19

  3. February 1, 2024

    Award notice

    PREVENT Preclinical Efficacy & Endpoint Biomarkers

    Awarded to The Univeristy of Texas MD Anderson Cancer Center, a Component of the Univeristy of Texas System 1515 Holcombe Boulevard Box 1676 Houston TX 770304009 US for $149,995,000. SAM.gov, notice 21852de14e454b62b14e13761138c1b4

  4. February 1, 2024

    Award notice

    PREVENT Preclinical Efficacy & Biomarkers

    Awarded to Weill Medical College of Cornell University 1300 York Avenue New York Ny 100654805 US for $149,995,000. SAM.gov, notice a6c2438194dc45b485e2a64eced25537

  5. February 1, 2024

    Award notice

    PREVENT Preclinical Efficacy & Endpoint Biomarkers

    Awarded to University of Oklahoma Po Box 26901 URP865, Suite 490 Oklahoma City Ok 731260901 US for $149,995,000. SAM.gov, notice f642a53e12b7455f90ee6e1a063d04f3

  6. September 16, 2024

    Solicitation

    Due February 28, 2023 at 10:00 AM EST. SAM.gov, notice 3fca19a50da6422c9e851d530af91d68

Points of contact

Also open from this buyer